1
عمومی::
bevacizumab
Suppression of proliferative retinopathy (phase 2) with injection of anti-VEGF antibody has been reported in many small case-series-eg, by Harder and colleagues.160 In a trial161 of 150 infants randomly assigned to receive laser or intravitreal bevacizumab treatment, recurrence was slightly less likely in the bevacizumab group than in laser-treated group at 54 weeks' postmenstrual age.
A significant treatment effect with bevacizumab was seen for retinopathy of prematurity in zone 1, but not zone 2.161 However, visual outcomes and adverse systemic effects were not reported.
Bevacizumab injected into the eye leaks into systemic circulation and reduces systemic VEGF concentrations,162 and might suppress systemic vascular growth or have other as-yet-unknown negative effects.163 Additional studies to assess the best choice of anti-VEGF drug, the optimum dose, the pharmacokinetics, and short-term and long-term safety are warranted.164,165
واژگان شبکه مترجمین ایران